Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FUTIBATINIB for Cholangiocarcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 77 adverse event reports in the FDA FAERS database where FUTIBATINIB was used for Cholangiocarcinoma.

Most Reported Side Effects for FUTIBATINIB

Side Effect Reports % Deaths Hosp.
Death 30 18.6% 30 9
Diarrhoea 29 18.0% 4 13
Hyperphosphataemia 22 13.7% 6 6
Nausea 21 13.0% 9 12
Disease progression 20 12.4% 5 6
Dry mouth 18 11.2% 4 9
Fatigue 18 11.2% 6 8
Off label use 16 9.9% 5 4
Vomiting 15 9.3% 5 11
Dry eye 13 8.1% 0 5
Constipation 12 7.5% 2 8
Decreased appetite 12 7.5% 1 7
Neuropathy peripheral 12 7.5% 1 7
Asthenia 11 6.8% 4 7
Dehydration 11 6.8% 5 8

Other Indications for FUTIBATINIB

Product used for unknown indication (23) Oesophageal carcinoma (11) Bile duct cancer (10)

Other Drugs Used for Cholangiocarcinoma

GEMCITABINE (1,181) CISPLATIN (923) CAPECITABINE (608) DURVALUMAB (444) OXALIPLATIN (441) PEMIGATINIB (431) FLUOROURACIL (341) GEMCITABINE\GEMCITABINE (292) IVOSIDENIB (277) NIVOLUMAB (250)

Related Pages

FUTIBATINIB Full Profile All Cholangiocarcinoma Drugs FUTIBATINIB Demographics FUTIBATINIB Timeline